267639-76-9 Usage
Description
Romiplostim has been developed and launched for the treatment of
thrombocytopenia in patients with ITP, an autoimmune blood disorder in
which there is autoantibody-mediated platelet destruction. Coating of
the platelets by autoantibodies results in accelerated ingestion by
macrophages. In addition to the destruction component, ITP is also
characterized by impaired platelet production. The primary physiological regulator of platelet production is thrombopoietin (TPO), a growth
factor that orchestrates its effects through the TPO (Mpl) receptor.Agonists of this receptor could, thereby, remediate the platelet production contribution of ITP. By binding to and activating the TPO receptor,
romiplostim serves as a TPO receptor agonist. As a recombinant fusion
protein, in this case coined as a peptibody, it was engineered to contain
two identical single-chain subunits, each consisting of a TPO-binding
domain linked to the C-terminus of a human IgG1 Fc domain designed to
increase the half-life of the protein. Although it binds to the TPO
receptor, romiplostim has no sequence homology to endogenous TPO,
which should mitigate the risks encountered with the first generation
predecessor, recombinant megakaryocyte growth and development
factor (MGDF); this truncated, non-glycosylated form of TPO conjugated
to PEG was halted during clinical studies because of the immunogenicity
of PEG-MGDF resulting in cross-reacting (neutralizing) antibodies
against endogenous TPO and subsequent severe, unrelenting thrombocytopenia. Romiplostim also avoids the side effects associated with the
generalized immunosuppressive agents previously employed for the
treatment of ITP and may prevent splenectomy, another common
treatment option.
Brand name
Nplate
Clinical Use
Fc-peptide fusion protein:
Treatment of chronic immune (idiopathic)
thrombocytopenic purpura (ITP)
Drug interactions
Potentially hazardous interactions with other drugs
None known
Metabolism
Mainly renal clearance.
Check Digit Verification of cas no
The CAS Registry Mumber 267639-76-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,7,6,3 and 9 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 267639-76:
(8*2)+(7*6)+(6*7)+(5*6)+(4*3)+(3*9)+(2*7)+(1*6)=189
189 % 10 = 9
So 267639-76-9 is a valid CAS Registry Number.